TIZIANA LIFE SCIENCES LTD (0RP) - Total Liabilities
Based on the latest financial reports, TIZIANA LIFE SCIENCES LTD (0RP) has total liabilities worth €7.35 Million EUR (≈ $8.59 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
TIZIANA LIFE SCIENCES LTD - Total Liabilities Trend (2021–2024)
This chart illustrates how TIZIANA LIFE SCIENCES LTD's total liabilities have evolved over time, based on quarterly financial data. See 0RP working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
TIZIANA LIFE SCIENCES LTD Competitors by Total Liabilities
The table below lists competitors of TIZIANA LIFE SCIENCES LTD ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fino Payments Bank Limited
NSE:FINOPB
|
India | Rs-7.47 Billion |
|
Sammok S-Form Co.Ltd
KQ:018310
|
Korea | ₩110.77 Billion |
|
Spruce Biosciences, Inc. Common Stock
NASDAQ:SPRB
|
USA | $10.51 Million |
|
Whitehawk Therapeutics, Inc.
NASDAQ:WHWK
|
USA | $9.85 Million |
|
Gala Precision Engineering
NSE:GALAPREC
|
India | Rs719.30 Million |
|
TRUFIN PLC
F:29U
|
Germany | €14.17 Million |
|
Suheung Capsul
KO:008490
|
Korea | ₩520.12 Billion |
|
Hanla IMS Co. Ltd
KQ:092460
|
Korea | ₩37.29 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down TIZIANA LIFE SCIENCES LTD's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TIZIANA LIFE SCIENCES LTD market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TIZIANA LIFE SCIENCES LTD's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TIZIANA LIFE SCIENCES LTD (2021–2024)
The table below shows the annual total liabilities of TIZIANA LIFE SCIENCES LTD from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €7.35 Million ≈ $8.59 Million |
+10.53% |
| 2023-12-31 | €6.65 Million ≈ $7.77 Million |
-3.74% |
| 2022-12-31 | €6.91 Million ≈ $8.07 Million |
-8.48% |
| 2021-12-31 | €7.55 Million ≈ $8.82 Million |
-- |
About TIZIANA LIFE SCIENCES LTD
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes… Read more